title: Amelioration by beraprost sodium, a prostacyclin analogue, of established renal dysfunction in rat glomerulonephritis model.
abstract: Effects of beraprost sodium, a chemically stable prostacyclin analogue, on renal dysfunction in an experimental rat model of glomerulonephritis were investigated. Beraprost sodium (30, 100 and 300 microg/kg) was orally given twice daily from the late stage of nephritis in which renal dysfunction was already developed. Beraprost sodium treatment inhibited the increase in urinary protein, serum creatinine and blood urea nitrogen, and the decrease in creatinine clearance. The elevation of serum creatinine was also inhibited by predonisolone (1 mg/kg). However, captopril (25, 50 and 100 mg/kg) and dipyridamole (20 and 60 mg/kg) failed to inhibit the elevation of serum creatinine. In the beraprost sodium-treated nephritic rats, the increase in mRNA levels for monocyte chemoattractant protein-1 (MCP-1) and collagen in the kidney was inhibited. These results suggest that beraprost sodium ameliorates developed renal dysfunction and is possibly an effective agent for the treatment of human glomerulonephritis.
authors.affiliation: Pharmaceutical Research Laboratories, Toray Industries, Inc., 1111 Tebiro Kamakura, Kanagawa 248-8555, Japan.
authors.forename: Masateru
authors.initials: M
authors.lastname: Yamada
authors.forename: Rie
authors.initials: R
authors.lastname: Sasaki
authors.forename: Nahoko
authors.initials: N
authors.lastname: Sato
authors.forename: Motohiro
authors.initials: M
authors.lastname: Suzuki
authors.forename: Mitsutaka
authors.initials: M
authors.lastname: Tamura
authors.forename: Teruo
authors.initials: T
authors.lastname: Matsushita
authors.forename: Hajimu
authors.initials: H
authors.lastname: Kurumatani
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D001806:Blood Urea Nitrogen; D001835:Body Weight / Q000187:drug effects; D002216:Captopril / Q000627:therapeutic use; D018932:Chemokine CCL2 / Q000096:biosynthesis / Q000378:metabolism; D003404:Creatinine / Q000652:urine; D004176:Dipyridamole / Q000627:therapeutic use; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000503:physiopathology; D007668:Kidney / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D007677:Kidney Function Tests; D007678:Kidney Glomerulus / Q000276:immunology; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011239:Prednisolone / Q000627:therapeutic use; D011507:Proteinuria / Q000139:chemically induced; D012333:RNA, Messenger / Q000096:biosynthesis; D011817:Rabbits; D051381:Rats; D011921:Rats, Inbred WKY; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000893:Anti-Inflammatory Agents; D018932:Chemokine CCL2; D010975:Platelet Aggregation Inhibitors; D012333:RNA, Messenger; C048081:beraprost; D004176:Dipyridamole; D002216:Captopril; D011239:Prednisolone; D003404:Creatinine; D011464:Epoprostenol